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Abstract
Activation of protein kinase C (PKC) has previously been shown to ameliorate the cholesterol transport defect in
Niemann Pick Type C1 (NPC1) cells, presumably by increasing the soluble levels of one of its substrates, vimentin.
This activity would then restore the vimentin cycle in these cells and allow vimentin-dependent retrograde transport to
proceed. Here, we further investigate the effects of PKC activation in NPC1 cells by evaluating different isoforms for
their ability to solubilize vimentin and correct the NPC1 cholesterol storage phenotype. We also examine the effects
of PKC activators, including free fatty acids and the PKC-specific activator diazoxide, on the NPC1 disease
phenotype. Our results indicate that PKC isoforms α, βII, and ε have the greatest effects on vimentin solubilization.
Furthermore, expression or activation of PKCε in NPC1 cells dramatically reduces the amount of stored cholesterol
and restores cholesterol transport out of endocytic vesicles. These results provide further support for the contribution
of PKCs in NPC1 disease pathogenesis and suggest that PKCs may be targeted in future efforts to develop
therapeutics for NPC1 disease.
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Introduction
The protein kinase C (PKC) family of enzymes is responsible
for a multitude of cellular processes through the enzymes’
ability to regulate proteins via signal transduction cascades [1].
The members of this kinase family are structurally and
functionally similar [2] and are categorized into conventional (α,
βI, βII and γ), novel (δ, ε, η, and θ), and atypical isoforms (ζ
and λ) [3]. These isoforms have been implicated in a variety of
diseases and pathological conditions over the years [4].
A previously unappreciated role for PKCs in Niemann-Pick
Type C (NPC1) disease was revealed by our observations that
the intermediate filament vimentin is hypophosphorylated in
NPC1 cells compared to Wt cells and that this
hypophosphorylation results from reduced PKC activity [5].
Vimentin is involved in a variety of cellular processes, including
vesicular membrane transport [6,7], signal transduction [8,9]
and cell motility [10]. Similar to NPC1 cells, cells lacking
vimentin are unable to transport LDL-derived cholesterol from
their lysosomes to the endoplasmic reticulum for esterification
[11]. The decreased vimentin phosphorylation in NPC1 cells
reduces the pool of soluble vimentin, likely disrupting the
vimentin cycle, which is necessary for transport to take place
[12,13]. Vimentin has been shown to be phosphorylated by
several proteins, including the PKCs [14] and in particular the α
[15], ε [10] and βII [16,17] isoforms.
In these studies we investigate the differences between WT
and NPC1 cells with respect to their levels of soluble vimentin
and evaluate the ability of the different PKC isoforms to
solubilize vimentin in NPC1 cells. We find that the PKC α, βII,
and ε isoforms can ameliorate the NPC1 cholesterol transport
block as determined by esterification assays and filipin staining.
Furthermore, fatty acid activators of PKCs have a similar and
additive effect, suggesting that specific PKC isoforms could be
therapeutically targeted for treatment of this disease.
Results
PKC Expression Increases the Levels of Soluble
Vimentin in NPC1 Cells
We have previously shown that NPC1 cells with missense or
null (NPC1o) mutations contain decreased or virtually
undetectable levels of soluble phosphorylated vimentin relative
to Wt cells, respectively [5]. Furthermore, the vimentin present
in NPC1 cells exists as large disorganized filaments
(dephosphorylated state) near the plasma membrane. Thus,
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NPC1 cells behave essentially as vimentin-null cells, which,
similar to NPC1 cells, are unable to esterify LDL-derived
cholesterol [11]. In extending those studies, we hypothesized
that decreased vimentin phosphorylation was the result of
protein kinase C (PKC) inhibition in NPC1 cells. In support of
this, we observed in that study that treatment of NPC cells with
the PKC activator phorbol-12-myristate-13-acetate (PMA)
increased levels of soluble vimentin and ameliorated the NPC
lipid storage phenotype, whereas conversely, treatment of WT
cells with PKC inhibitors resulted in the disappearance of
soluble vimentin in those cells. These results strongly implicate
PKC in the maintenance of the soluble vimentin pool in cells
and by extension normal lysosomal cholesterol efflux. Here we
extend those studies by evaluating different PKC isoforms and
their effects on soluble vimentin levels in NPC cells.
The PKC isoforms α, βII, and ε have been implicated in
vimentin phosphorylation [10,17,18]; therefore, we first focused
our studies on these isoforms. They were transiently expressed
in human NPC1 cells and their effects on soluble vimentin
levels were characterized. Expression of PKC βII caused a
significant increase in soluble vimentin levels (~38-fold higher
than untransfected NPC1 cells), which was higher than the
levels seen in Wt cells (~20-fold higher than NPC1 cells),
whereas expression of PKCs α or ε caused smaller but still
significant increases (~3-fold and ~7-fold, respectively) in
soluble vimentin levels (Figure 1). As a control, expression of
Rab9 in these cells also led to a significant increase (~30-fold)
in soluble vimentin, consistent with what we previously reported
[5]. Interestingly, all three isoforms resulted in an increase of
soluble Rab9 levels to a similar degree (~2500-fold higher than
untransfected NPC1 cells). Furthermore, insoluble vimentin
levels decreased as soluble vimentin levels increased in PKC-
expressing cells, suggesting that the increase in soluble
vimentin was due to solubilization (phosphorylation) of
insoluble vimentin (Figure 1A).
Similarly, in the severely affected NPC10 cells, which
normally have almost no detectable soluble vimentin,
expression of any of the three PKC isoforms resulted in
increased levels of soluble vimentin (Figure 1B). With respect
to vimentin solubilization, all three isoforms work equally well in
the NPC10 cells, in contrast to the NPC1 cells, in which the βII
isoform seemed to be the most effective in solubilizing
vimentin. Furthermore, soluble Rab9 levels also increased to
similar levels as a result of PKC expression (Figure 1B), a
result also seen in PKC-expressing NPC1 cells (Figure 1A).
PKC Expression Induces Rab9 Dissociation from
Vimentin
The observations that the small GTPase Rab9 is trapped in
vimentin filaments in NPC1 cells [5] and that Rab9
overexpression corrects the NPC1 phenotype [19] strongly
suggest that Rab9 availability is reduced in NPC1 cells. The
disease cells may attempt to compensate for this deficit by
upregulating Rab9 protein expression. This idea is supported
by the fact that NPC1 cells do contain more Rab9 protein than
Wt cells (Figure 1A and [19]). As described above, PKC
expression increased not only soluble vimentin levels but also
soluble Rab9 levels significantly (Figure 1A and 1B). To
determine whether the increased Rab9 levels in PKC-
expressing cells was a result of Rab9 release from insoluble
vimentin after it was phosphorylated, we performed PKC
assays in vitro with nine purified PKC isoforms using the
insoluble vimentin fraction of NPC1 cell lysates as the PKC
substrate. All isoforms were able to effect Rab9 release from
insoluble vimentin to varying degrees (Figure 2), suggesting
that, at least in vitro, most PKC isoforms can catalyze vimentin
phosphorylation and Rab9 release. Interestingly, PKC α
caused the greatest increase in Rab9 release, while PKC βII
and ε were less effective and PKC γ was almost ineffective.
These results differ from the results of transiently transfected
PKC-expressing cells, which suggest that PKC βII is more
effective in increasing soluble vimentin levels than PKC α and ε
(Figure 1A). The discrepancies in isoform effectiveness may be
due to the nature of the assays, the inherent activity of each
isoform, or the in vivo subcellular location of the different
isoforms and their access to vimentin [10,16,17,20]; however, it
is clear that PKC is able to solubilize vimentin and in doing so
release entrapped Rab9.
Overexpression of PKCs Induces a Partial Correction of
the NPC1 Phenotype
Based on the data above and observations that Rab9
overexpression results in increased soluble vimentin and
correction of the NPC1 phenotype [5], we next determined
whether increased vimentin solubility caused by PKC
overexpression would also result in correction of the NPC1
phenotype. NPC1 CHO (M12) cells containing a deletion of the
NPC1 locus [21] were transfected with PKC α or PKC ε and the
amount of LDL-derived free cholesterol transported from the
E/L system to the ER for esterification by acyl-CoA: cholesterol
acyltransferase (ACAT) [22] was measured. As expected,
esterification levels for M12 cells were less than 10% of the
esterification activity of the parental Wt CHO cells (Figure 3),
which is consistent with a block in cholesterol transport out of
the E/L system. Expression of PKC α or PKC ε ameliorated the
cholesterol transport block, increasing the level of M12 cell
esterification by approximately 4- and 6.5-fold, respectively,
over that of untransfected M12 cells (Figure 3, +PKCα,
+PKCε). These results indicate that solubilization of vimentin
mediated by expression of PKCs can partially release the
NPC1 lipid transport block.
Cholesterol storage in PKC-transfected cells was also
determined qualitatively by staining with filipin, a fluorescent
probe that binds to free cholesterol [23]. This analysis yielded
similar results to the esterification studies shown in Figure 3.
Cells that were positive (as determined by GFP co-expression)
for PKCα, PKCε, or PKCβII showed significantly less filipin
staining than surrounding untransfected cells (Figure 4). These
results were similar to those seen in cells over-expressing
Rab9 (Figure 4, Rab9), which has previously been shown to
correct the NPC1 cholesterol storage phenotype [19].
Exposure to Fatty Acids Increases Soluble Vimentin
Levels in NPC1 Cells
Fatty acids and in particular oleic acid have been shown to
induce PKC activity [24], whereas a downstream metabolite of
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linoleic acid, DCP-LA (8-[2-(2-pentyl-cyclopropylmethyl)-
cyclopropyl]-octanoic acid), has been shown to potently
activate PKC ε [25,26]. Furthermore, we have shown
previously that NPC1 endosomes store large amounts of fatty
acids [27], which could potentially limit the amount of free fatty
acids available to the cell for PKC activation and other
processes.
Figure 1.  Effects of transient PKC expression on vimentin solubilization in human NPC1 cells.  Representative western blot
analyses of soluble and insoluble vimentin levels in human NPC1 3123 (A) and human nullNPC10 (B) cells transfected with PKC ε,
β, or α show that the three isoforms increase levels of soluble vimentin and Rab9 with a concurrent decrease of insoluble vimentin
relative to untransfected cells (-). The levels of vimentin solubilized are similar to that seen in cells expressing Rab9 (Rab9). The
blots shown are representative of at least 3 independent experiments.
doi: 10.1371/journal.pone.0074169.g001
PKC Activation in NPC1
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To determine if exogenously added fatty acids can increase
vimentin solubilization in NPC1 cells, human NPC1 fibroblasts
were treated with oleic or linoleic acid for 48 hours and the
levels of soluble vimentin in cell lysates were analyzed. As
expected, NPC1 fibroblasts contain very little soluble vimentin
(Figure 5A and [5]). Treatment with either oleic or linoleic acid
significantly increases the amount of soluble vimentin, with
oleic acid being slightly more effective. These results suggest
that exogenously added fatty acids can effect vimentin
solubilization in NPC1 cells, presumably by activating PKCs.
Exposure to Fatty Acids Induces Correction of the
NPC1 Phenotype
Since fatty acids increase solubilization of vimentin in NPC1
cells, it seemed reasonable that they might also improve the
NPC1 phenotype. M12 CHO cells (Figure 5B) and human
NPC1 fibroblasts (Figure 5C) were treated with each fatty acid
and then stained with filipin. As expected, Wt cells (Figures
5B/C, 1) stain very weakly with filipin, whereas NPC1 (Figures
5B/C, 2) cells contain bright, punctate staining that is indicative
of free cholesterol in endocytic vesicles. Filipin fluorescence in
NPC1 cells from both species was significantly decreased after
exposure to either fatty acid (Figures 5B/C, 3 and 4). Following
quantitation of filipin fluorescence levels by integrated
morphometry, both fatty acids were found to dramatically
reduce the levels of cholesterol accumulation in both NPC1 cell
lines, reducing filipin fluorescence to ~75% of levels in
untreated cells (Figure 5B/C, graphs). Human fibroblasts
exhibit more heterogeneous filipin staining patterns than either
CHO or mouse NPC1 cell lines, which is reflected in the higher
standard deviation in untreated 3123 cells (Figure 5C, graph).
The effect of fatty acids on cholesterol esterification in M12
cells was also evaluated. Linoleic acid increased cholesterol
esterification by greater than 2-fold compared to untreated M12
cells (Figure 3, +Lin). In M12 cells treated with oleic or linoleic
acids followed by expression of PKC ε, the correction of the
NPC1 phenotype was more pronounced, with esterification
levels that were ~3.5-fold over untreated cells (Figure 3,
+PKCε/oleic and +PKCε/linoleic). These results suggest that
fatty acids and PKC expression have an additive effect on
correction of the NPC1 cholesterol transport block.
To further characterize the effects of fatty acids on the NPC
phenotype, we also tested the ability of docosahexanoic acid
(DHA) and a metabolite of linoleic acid, DCP-LA, for their ability
to decrease cholesterol storage in M12 CHO cells. Both fatty
acids have been shown to potently activate PKC ε [24,28].
Treatment of M12 CHO cells with these compounds overnight
resulted in decreased cholesterol storage (Figure 6C/D)
relative to untreated cells (Figure 6B). DCP-LA (Figure 6C) was
slightly more effective than DHA (Figure 6D). Quantitation of
filipin intensity in these cells revealed that both compounds
reduced cholesterol storage in M12 CHO cells by ~50% (Figure
6G), lending further support to the positive effect of free fatty
acids on the NPC disease phenotype, possibly through
activation of PKC ε.
To provide further support for the role of PKCs in NPC
rescue, M12 cells were treated with diazoxide, which has been
shown to activate PKC ε [29]. This treatment resulted in
reduced cholesterol accumulation in M12 CHO cells (Figure
6F) relative to untreated cells (Figure 6E). Quantitation of the
filipin intensity in these cells indicated that diazoxide reduced
cholesterol storage by ~50%, similar to the results seen with
the free fatty acids (Figure 6G).
To further confirm the positive effects of DCP-LA and fatty
acids on the NPC1 phenotype, human NPC1 cells were treated
with DCP-LA, fatty acids, or PMA to activate PKCs. Cells were
then labeled with BODIPY-LacCer, which has previously been
shown to provide a dynamic view of the endocytic pathway
[30]. Following absorption to the plasma membrane, the
LacCer sphingolipid enters normal cells via endocytosis and
Figure 2.  Rab9 release from insoluble vimentin fraction of NPC1 cell lysates.  The insoluble vimentin fraction from NPC1 cell
lysates was incubated with various PKC isoforms. All isoforms tested can effect Rab9 release to some degree from the insoluble
vimentin fraction, with PKCα being the most effective and PKCγ being the least effective. The blots shown are representative of at
least 3 independent experiments.
doi: 10.1371/journal.pone.0074169.g002
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eventually reaches the trans-Golgi network (TGN; [30]). Due to
the lipid transport block in NPC1 cells however, this
sphingolipid is trapped in endosomes and its targeting to the
TGN is dramatically inhibited [30]. Human NPC1 cells treated
as indicated in Figure 7 show a dramatic improvement in lipid
transport with the BODIPY-LacCer effectively reaching the
TGN (Figure 7; arrows) compared to untreated cells that show
only punctate, endosomal fluorescence (Figure 7A). These
results provide further support that these agents are able to
release the NPC1 lipid block.
Taken together, these results indicate that exposure to free
fatty acids, which may act by activating PKC ε, has a positive
effect on the NPC cholesterol storage phenotype and provide
the rationale for further exploration.
Discussion
We previously reported that Rab9 expression in NPC1 cells
restored lipid transport from the E/L system and normalized
cholesterol esterification [19] and subsequently showed that
Rab9 was entrapped in insoluble vimentin filaments in NPC1
cells [5]. We hypothesized that accumulated lipids such as
sphingosine [31,32] in NPC1 cells might exert an inhibitory
effect on various PKC isoforms, resulting in a disruption of the
vimentin phosphorylation/dephosphorylation cycle [19].
To characterize the nature of PKC inhibition and vimentin
hyposphorylation in NPC1 cells, we expressed a number of
PKC isoforms (α, βII and ε) in NPC1 cells and characterized
their effect on vimentin solubilization and correction of the
NPC1 phenotype. All three isoforms had a positive effect on
Figure 3.  Effects of PKCs and fatty acids on cholesterol esterification in M12 NPC1 CHO cells.  M12 cells were treated with
50µg/ml fatty acids for 2 days and then transfected with the indicated PKC isoforms. Following transfection, cholesterol transport
was assessed by esterification assay. Both free fatty acids and PKCs alleviate the cholesterol transport defect of NPC1 cells and
their effects appear to be additive.
doi: 10.1371/journal.pone.0074169.g003
PKC Activation in NPC1
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Figure 4.  Effects of transient PKC expression on the NPC1 phenotype.  M12 cells were transfected with PKC isoforms or Rab9
for 48 hrs and then analyzed by filipin staining for cholesterol storage. Cells positive for transfection stain positive for GFP (left
panel) and show decreased filipin staining (outlined cells, right panel) compared to surrounding untransfected cells, confirming the
role of PKCs in mobilizing stored cholesterol from the NPC1 endosomes. Bar, 20μ.
doi: 10.1371/journal.pone.0074169.g004
PKC Activation in NPC1
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vimentin solubilization to varying degrees (Figure 1).
Furthermore, as we predicted, this PKC-induced vimentin
solubilization was accompanied by the release of the
entrapped Rab9 (Figure 1).
To further determine which PKC isoforms might be more
effective in vimentin phosphorylation and release of Rab9, we
tested eight different PKC isoforms in an in vitro assay.
Interestingly, most isoforms were able to release Rab9 from
vimentin to varying degrees (Figure 2), which may not be in
case in vivo. This discrepancy is likely due to the different in
vivo subcellular locations of PKC isoforms and their access to
vimentin filaments [16,20]. However, it is also possible that
vimentin may not be a direct substrate for certain PKCs, as has
been shown with regards to PKC ε-controlled phosphorylation
of vimentin [10]. In that study, PKC ε mediated vimentin
phosphorylation, which was shown to be critical for proper
integrin recycling through the cell. Our studies indicate that
expression of PKC isoforms in NPC1 cells results in the partial
Figure 5.  Effects of fatty acids on vimentin solubilization and the NPC1 phenotype.  (A) Human NPC1 3123 cells were treated
with 50µg/ml linoleic or oleic acid for 24 hrs, after which the levels of soluble vimentin were analyzed by Western blotting.
Cholesterol storage in NPC1 CHO (B) or human 3123 (C) cells was analyzed by filipin staining. Fluorescence intensity was
quantitated in at least 150 cells for each sample. The bar graph represents average values ±SEM from 3 independent experiments.
* and *** denote statistically significant differences between treated and untreated cells with P<0.05 and P<0.0001, respectively, as
determined by Student’s t-test.
doi: 10.1371/journal.pone.0074169.g005
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Figure 6.  Effects of PKC activation on the NPC1 phenotype.  NPC1 CHO cells (B and E) were treated with 100µM DCP-LA (C),
10µM DHA (D), or 100µM diazoxide (E) and cholesterol storage was quantified by filipin fluorescence. (A) Wt CHO cells. Filipin
intensity was quantitated in at least 150 cells for each sample. The bar graph represents average values ±SEM from 3 independent
experiments. *, **, and *** denote statistically significant differences between treated and untreated cells with P<0.05, P<0.01 and
P<0.0001, respectively, as determined by Student’s t-test.
doi: 10.1371/journal.pone.0074169.g006
PKC Activation in NPC1
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Figure 7.  Effects of PKC activation on sphingolipid transport.  Human NPC1 3123 cells were treated with (B) 20µM DCP-LA,
(C) 2µg/ml oleic acid, (D) 2µg/ml linoleic acid, or 100nM PMA for 48 hours before BODIPY-LacCer staining was performed. In
untreated cells (A), transport of the lipid to the TGN is inhibited and staining is visible only in punctate endocytic vesicles. In
contrast, in treated cells the lipid can be seen in the TGN (arrows) in treated cells, indicating release of the transport block that
characterizes NPC1.
doi: 10.1371/journal.pone.0074169.g007
PKC Activation in NPC1
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correction of the NPC1 disease phenotype, i.e., cholesterol
accumulation in the endosomal/lysosomal system.
Many studies have shown that long chain fatty acids such as
oleic and linoleic, along with downstream metabolites such as
DCP-LA, are able to activate PKC ε [24,25], an isoform shown
to phosphorylate vimentin filaments [10]. Since we and others
have previously reported that the availability of free fatty acids
may be limited in NPC1 cells [27,33], we tested the hypothesis
that exogenously added fatty acids might have a positive effect
on the NPC1 phenotype, presumably by activating PKC ε and
leading to phosphorylation of vimentin and release of Rab9. As
predicted, addition of oleic acid, linoleic acid, or DCP-LA
resulted in an increase of soluble vimentin in NPC1 cells
(Figure 5). Furthermore, fatty acid addition resulted in a
significant improvement in cholesterol esterification by NPC1
cells (Figure 3), indicating that lipid transport from the E/L
system was restored. Finally, we tested the ability of diazoxide,
a known activator of PKC ε [29], to correct the NPC1
phenotype, providing further support for the involvement of
insufficient PKC phosphorylation of vimentin in contributing to
NPC1 pathogenesis. In agreement with the results presented
here, diazoxide was able to reduce cholesterol accumulation in
NPC1 cells by 50% (Figure 6). Although our results with
multiple PKC ε activators strongly suggest that PKC ε is
mediating these changes within the NPC cells, we cannot
exclude the possibility that these agents may be acting through
some other pathway or protein besides PKC. Further studies to
show PKC activation would clarify the role of PKC expression
in the amelioration of the NPC1 phenotype.
Our data are consistent with previous observations of
aberrant PKC expression in NPC mouse liver [34]. In those
studies the expression of PKC α, δ, ε, and ζ were evaluated by
immunoblot. Whereas PKC α and δ were about 3-fold higher in
NPC1 livers compared to Wt livers, PKC ε was not significantly
increased and PKC ζ was higher only in heterozygous livers. It
is interesting to postulate that PKC ε does not render itself
amenable to upregulation but can be activated, via fatty acids
for example, and such activation can yield beneficial results in
NPC1 cells. There is strong evidence that PKC ε is responsible
for phosphorylating vimentin, which in turn controls the
vesicular transport of various ligands such as integrins [10].
Considering the difficulties of delivering proteins as
therapeutics, which are significantly amplified in diseases with
neuropathology such as NPC1, a small lipid activator of a key
regulator such as PKC ε would be greatly advantageous.
These results suggest that identification of the PKC isoform(s)
responsible for vimentin phosphorylation may provide new
therapeutic targets for the treatment of Niemann-Pick type C
disease and probably for a number of other lysosomal storage
disorders with neuropathology that lead to E/L lipid
accumulation [35].
Materials and Methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM), trypsin, L-
glutamine, gentamicin, and NuPage gels and buffers were
obtained from Invitrogen (Carlsbad, CA) while FBS was from
Hyclone, Thermo Scientific (Rockford, IL). The monoclonal
anti-vimentin (V9), conjugated anti-mouse-IgG and anti-rabbit-
IgG antibodies were from Santa Cruz Biotechnologies, Inc.
(Santa Cruz, CA). The anti-GAPDH antibody was from Millipore
(Billerica, MA) and the anti-Rab9 polyclonal antibody has been
described elsewhere [27]. Filipin was from Polysciences, Inc.
(Warrington, PA). Lumilight Plus substrate and FuGENETM 6
transfection reagent were both from Roche Diagnostics
(Indianapolis, IN). [9,10-3H(N)] oleic acid (15 Ci/mmol) was
obtained from NEN Life Science Products (Boston, MA) and
LDL was from EMD Biosciences Inc. (La Jolla, CA). All other
chemicals were acquired from Sigma-Aldrich (St. Louis, MO).
Cell culture and transfection
The human wild-type fibroblast (GM05387), NPC10 fibroblast
(GM09341), and NPC1 fibroblast (GM03123) cell lines were
obtained from Coriell Cell Repositories (Camden, NJ). The M12
Chinese hamster ovary (CHO) cell line and its wild-type
parental line were a kind gift of Dr. Daniel Ory (Washington
University, St. Louis, MO). Fibroblast cell lines were cultured in
DMEM and CHO cells were cultured in DMEM/F12 (50:50)
medium, supplemented with 10% FBS, 2 mM L-glutamine, and
50 µg/ml gentamicin in a humidified incubator at 37°C with 5%
CO2.
The cDNA for PKC α (generous gift of Dr. A. Toker,
University of California at San Diego, CA) was cloned into the
bicistronic vector pIRES (Stratagene), which contains GFP for
monitoring successful transfection. The cDNAs for PKC βII
(generous gift of Dr. AC Newton, University of California at San
Diego, CA), and PKC ε (ATCC) were cloned into vector
pYDual, which expresses a nuclear-targeted RFP (Ioannou,
unpublished). A Rab9-YFP fusion construct (described in [5])
was used for Rab9 expression. Transient overexpression was
achieved by transfecting cells at 70% confluency using the
FuGENETM 6 reagent (Roche Diagnostics) according to the
manufacturer’s suggestions.
Protein analyses
Transfected cells were harvested with PBS containing 2mM
EDTA at 2 days post-transfection. Soluble and insoluble cell
fractions were prepared as described previously [5]. Briefly, to
obtain the soluble/cytoplasmic fraction, cells were incubated on
ice for 30 min in cold “phospho” buffer [150 mM NaCl, 20 mM
NaF, 100 µM Na 3VO4, 20 mM Hepes, pH 7.5), 1% (v/v) Igepal,
10% (v/v) glycerol, and 1 µl/20mg tissue of protease inhibitor
cocktail] and then centrifuged for 20 min at 14,000 rpm at 4°C;
the clear supernatant was frozen in aliquots at a concentration
of 1 µg/µl. The pellet (insoluble fraction) was washed 3 times in
ice-cold PBS containing 2 mM EDTA and then resuspended in
a volume of “Triton” buffer [PBS, 1% (w/v) SDS, and 0.1% (v/v)
Triton X-100] equal to the “phospho” buffer. This solution was
boiled for 10 min and sonicated until the solution became clear.
The protein concentration of this fraction was adjusted to 1
µg/µl according to the protein concentrations determined for
the soluble/cytoplasmic fraction. Protein concentrations were
determined using the fluorescamine method as we have
described [36].
PKC Activation in NPC1
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For immunoblotting, 10 µg protein was resolved through a
4-12% Bis-Tris precast gel (Invitrogen, Carlsbad, CA) and then
transferred onto a Protran membrane using an XCell II
apparatus (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Blots were processed as described
previously [27].
For Rab9 dissociation studies, 1.0 x 107 NPC1 3123 cells
were collected in ice-cold PBS and lysed by sonication 4 times
for 10s each. The lysate was centrifuged at 14,000 rpm for 10
minutes to separate the soluble from the insoluble fractions and
the total protein concentration was determined using a modified
Bradford assay (Bio-Rad, Hercules, CA). An equal amount of
each insoluble fraction was mixed with each purified PKC
isoform from a PKC isozyme panel (Sigma, St. Louis, MO) and
incubated for 60 min at 37°C. An equal volume of each sample
was resolved through a 4-12% Bis-Tris precast gel, transferred
to a membrane, and processed as described above.
Cholesterol esterification
The preparation of [3H] oleate substrate and esterification
assays were performed as previously described [5]. Cells were
treated with 50µg/ml fatty acid for 2 days and then transfected
with PKE α or PKC ε for 24 hrs before esterification assays. All
values were generated in triplicate and normalized for total cell
protein.
Immunofluorescence microscopy
For filipin staining in transfected cells, cells were transfected
with PKC or Rab9 using Fugene 6 according to the
manufacturer’s recommendations. After 48 hrs, cells were
stained with filipin as we have previously described [37]. Cells
were mounted onto slides using Fluoromount-G
(SouthernBiotech, Birmingham, AL) and analyzed on a Nikon
Eclipse microscope fitted with a charge-coupled-device camera
(Nikon, Melville, NY). Images were acquired with MetaVue
software and then deconvoluted using AutoDeblur software
from AutoQuant Imaging, Inc (Troy, NY).
For quantitation of filipin fluorescence, cells were seeded at 3
x 105 cells/well in 6-well dishes and allowed to settle overnight,
after which the medium was replaced with medium containing
10% lipoprotein deficient serum (LPDS) for 4 days. Cells were
incubated with oleic/linoleic acids for 48 hours, DCPLA/DHA for
24 hrs, or diazoxide for 72 hrs before fixing and staining with
filipin as we have previously described. Images were acquired
using the same exposure time for all samples. Fluorescence
intensity was determined using the integrated intensity function
of MetaVue software; at least 150 cells were quantitated for
each sample and each experiment was repeated 3 times.
For analysis of sphingolipid transport, cells were incubated
with oleic/linoleic acids, DCP-LA, or PMA for 48 hours before
BODIPY-LacCer staining was performed as previously
described [30].
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